Market Trends of Global Hydrophobic Interaction Chromatography Industry
This section covers the major market trends shaping the Hydrophobic Interaction Chromatography Market according to our research experts:
Monoclonal Antibodies Segment is Expected to Witness Growth Over The Forecast Period
Monoclonal antibodies are identical antibodies produced artificially through genetic engineering from parent cells. The monoclonal antibodies are used extensively in cancer treatment, bone marrow transplantation, and many other therapeutic applications. Hydrophobic interaction chromatography is widely used in purification of monoclonal antibodies.
According to The University of Texas MD Anderson Cancer Center January 2022 update, monoclonal antibodies are transforming how physicians treat cancer and other diseases, including COVID-19. These medications imitate the immune system's built-in defense against infection. Many cancer forms are treated using monoclonal antibodies. They can be used either alone or in conjunction with other cancer treatments, and they are administered to patients via an infusion. Depending on the antigen that each monoclonal antibody is targeting, it may function in single or several ways. Owing to the advantages of monoclonal bodies, its usage is projected to propel during the forecast period.
In addition, technological advancements, product launches, approval, along with partnerships by the key market players is likely to boost the segment growth. For instance, in March 2022, Sanofi and Seagen collaborated to create and market a variety of novel antibody-drug conjugates for three cancer targets. The advancements in the monoclonal antibodies are fueling the usage of hydrophobic interaction chromatography and propel the segment growth during the forecast period.
North America is Expected to Dominate The Hydrophobic Interaction Chromatography Market Over The Forecast Period
North America is expected to dominate the market owing to factors such as the rising incidence of cancer, the strong presence of industry players in the region, better healthcare infrastructure, awareness among people and healthcare industry stakeholders about available technologies, and the increasing research and development investment in the region.
According to the American Cancer Society, Cancer Statistics 2022, 1,918,030 new cancer cases and 609,360 cancer deaths are predicted to occur in the United States in 2022. Also, according to the Canadian Cancer Statistics November 2021 report, an estimated 2 in 5 Canadians were likely to be diagnosed with cancer in their lifetime. It stated that an estimated 229,200 Canadians was predicted to be diagnosed with cancer in 2021. The high burden of cancer in the region is likely to boost the research and development activities to prepare monoclonal antibodies for its treatment which is projected to boost the utility of hydrophobic interaction chromatography in the region.
Factors such as increasing research and development in developing monoclonal antibodies for various applications in various diseases, especially cancer, coupled with technological advancements, are fueling market growth in the region during the forecast period. For instance, In August 2022, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) received the United States Food and Drug Administration approval for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC). Enhertu is a specially developed HER2-directed antibody drug conjugate (ADC). Such advancements in the monoclonal antibodies for treatment of cancer is projected to boost the market during the forecast period.
